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Abstract
Objective—To examine disease activity versus treatment as lymphoma risk factors in systemic
lupus erythematosus (SLE).
Methods—We performed case–cohort analyses within a multisite SLE cohort. Cancers were
ascertained by regional registry linkages. Adjusted HRs for lymphoma were generated in
regression models, for time-dependent exposures to immunomodulators (cyclophosphamide,
azathioprine, methotrexate, mycophenolate, antimalarial drugs, glucocorticoids) demographics,
calendar year, Sjogren’s syndrome, SLE duration and disease activity. We used adjusted mean
SLE Disease Activity Index scores (SLEDAI-2K) over time, and drugs were treated both
categorically (ever/never) and as estimated cumulative doses.
Results—We studied 75 patients with lymphoma (72 non-Hodgkin, three Hodgkin) and 4961
cancer-free controls. Most lymphomas were of B-cell origin. As is seen in the general population,
lymphoma risk in SLE was higher in male than female patients and increased with age.
Lymphomas occurred a mean of 12.4 years (median 10.9) after SLE diagnosis. Unadjusted and
adjusted analyses failed to show a clear association of disease activity with lymphoma risk. There
was a suggestion of greater exposure to cyclophosphamide and to higher cumulative steroids in
lymphoma cases than the cancer-free controls.
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Conclusions—In this large SLE sample, there was a suggestion of higher lymphoma risk with
exposure to cyclophosphamide and high cumulative steroids. Disease activity itself was not clearly
associated with lymphoma risk. Further work will focus on genetic profiles that might interact
with medication exposure to influence lymphoma risk in SLE.
Lymphoma risk in systemic lupus erythematosus (SLE) is of considerable interest; patients
and practitioners are both concerned about the potential increased risk from
immunosuppressive SLE treatments. The most definitive data on lymphoma risk in SLE was
generated from our recently updated large, multicentre, international cohort study (16 409
patients at 30 centres), which confirmed a slight increased risk for all cancers combined and
a striking threefold increased risk for haematological cancers, particularly lymphoma.1
However, the relative importance of disease activity versus treatment in driving lymphoma
risk is unknown. Our objective was to determine the relative importance of disease activity
versus treatment in SLE.
METHODS
A case–cohort study was performed within the large multisite SLE cohort referred to in the
introduction, with the participation of collaborating centres from two research networks, the
Systemic Lupus International Collaborating Clinics and the Canadian Network for Improved
Outcomes in Systemic Lupus, as well as other collaborators. These included centres from
Calgary, Montreal, Toronto, Winnipeg, Baltimore, Boston, Chapel Hill, Chicago, New York
City, Los Angeles, Pittsburgh, San Francisco Bay Area, South Carolina, Mexico City,
Copenhagen (Denmark), Birmingham (UK), London (UK), Bizkaia (Spain), Hannover
(Germany), Lund (Sweden) and Seoul (South Korea). Cancers were ascertained by regional
registry linkages, except at Boston—where lymphomas were ascertained through validated
hospital discharge summaries—and Mexico City—where lymphomas were ascertained
through medical chart review.
We used the case–cohort study design for optimal flexibility and efficiency. In this design,
exposure and covariate information is collected from all cases and a random representative
sample of the cohort at each centre as the source for controls. To ensure the efficient use of
available control data, we included within the control pool 100% of the cohort (cancer-free
at cohort entry) when the necessary data were already available electronically, and, when
centres had to perform chart review to provide data, we included a lower percentage of their
cohort (cancer-free at baseline), ranging from 2.5% to 10% of control subjects. Observations
within these subsets were then appropriately weighted using the Barlow method as
previously described.2
All study subjects had definite SLE according to the revised American College of
Rheumatology (ACR)3 or clinical criteria. (Each investigator follows a cohort of clinically
confirmed SLE patients in follow-up, the vast majority of whom fulfil ACR criteria.) We
included only lymphomas that had occurred after entry into the lupus cohort at each centre;
the index time for each risk (case–control) set was the date of the case’s lymphoma
occurrence expressed as time elapsed since SLE diagnosis. The analyses were thus adjusted
for SLE disease duration. The controls for each risk set, for each lymphoma case,
represented all the subcohort members who remained cancer-free up to that index time.
Cancer registries generally require at least one calendar year period to have elapsed before
they can confirm that their cancer data are adequately complete and accurate, so the end of
the observation interval for each centre’s SLE cohort was based on the earliest of that date,
or the last date the patient was seen in clinic (or date of death, if relevant).
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We performed descriptive analyses of our variables and used modified Cox proportional
hazards regression to calculate the unadjusted and fully adjusted HR for lymphoma related
to each covariate in our model, which included demographics (age, sex, race/ethnicity,
geographic residence), calendar year, medication exposure and disease activity. Sjogren’s
syndrome, an auto-immune phenomenon characterised by dry eyes and mouth and anti-Ro/
anti-La antibodies, can either occur as a primary syndrome or secondarily in a disease such
as SLE. Because of the strong lymphoma risk seen in primary Sjogren’s syndrome,4 the
presence of ‘secondary Sjogren’s syndrome’ in our SLE subjects was also included as a
potential risk factor.
Partially adjusted models were also performed (with the same modified Cox proportional
hazards regression approach) using stepwise selection. Although the full model adjustment
allows us in principle to distinguish between all independent effects, it does so at the cost of
decreased precision. The partially adjusted model can minimise the variance that results
from strong correlations between a larger number of predictors, thus providing more precise
estimation. In the partial model, disease activity was forced in, as it was a primary exposure
of interest in this study.
The data on clinical characteristics and all medications were prospectively recorded in the
clinic database and/or medical records at each centre. Data from each centre were either
exported as character-encoded files or abstracted from these sources using a standardised
form, and compiled in Montreal. All time-varying variables were treated as time-dependent,
assessed for each case–control risk set at the index time. Age was a continuous variable,
geographic residence was included as a dichotomous variable indicating whether or not a
given centre was outside North America, and presence or absence of Sjogren’s syndrome
was based on clinical judgment and documentation within each participating centre’s
records (as opposed to requiring patients to fulfil specific criteria for Sjogren’s).
Medications were included as time-dependent variables for ever/never use for all the
medications listed in table 1. Since there is some concern about dose effects for
cyclophosphamide and azathioprine (AZA), we also included a variable indicating
cumulative dose category for these agents. To better control for corticosteroid use, which
could be associated with disease activity and potentially with lymphoma risk,5 we also
included a cumulative dose categorical variable. Sensitivity analyses were performed
lagging cyclophosphamide by 5 years (based on literature suggesting that malignancies may
arise many years after exposure).6 Here, any lymphomas occurring within the 5-year period
immediately after initiation of cyclophosphamide were not attributed to that exposure.
Disease activity was characterised on the basis of SLE Disease Activity Index (SLEDAI, V.
2K) scores; for each risk set, we created an Adjusted Mean SLEDAI-2K score.7 This
involves calculating the area under the curve of SLEDAI-2K scores over time. Here, the
area under the curve between each two visits is the average of the SLEDAI-2K values at
those two visits multiplied by the length of time between the two visits. All the calculated
areas are then summed and divided by the total length of the time period. The adjusted mean
SLEDAI-2K has the same units as SLEDAI-2K and is interpreted in the same way. The
adjusted mean SLEDAI-2K has been shown to be a valid measure of SLE activity. To aid
interpretation of our results, the variable for high disease activity was dichotomised, where
high activity was represented by an adjusted mean SLEDAI-2K value of 6 or more.
The SLEDAI-2K is normally completed by a physician, but, at two centres (Calgary and San
Francisco), disease activity elements were self-reported by patients.8 At the Birmingham UK
centre, cumulative disease activity was measured with the British Isles Lupus Assessment
Group index. For these three centres (Calgary, San Francisco and Birmingham UK), high
activity was defined as the highest quartile of the adjusted mean activity scores. Although
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the disease activity measures from these centres were initially included when we
dichotomised adjusted mean disease activity scores for the case–control sets, since this
measure is not completely interchangeable with the formal SLEDAI-2K, we performed
sensitivity analyses excluding these centres.
Since lymphomas constitute a heterogeneous group of diseases, as a sensitivity analysis, we
repeated our analyses focusing on lymphomas that were only of B-lymphocyte (as opposed
to T-lymphocyte) origin.
For all analyses, Stata V.9 was used, including the ‘stcascoh’ routine for setting up the case–
cohort data, and ‘stcox’ for the regression analysis, with Barlow weights and robust SE.
RESULTS
In total, we studied 75 lymphoma cases (in 75 individuals), and the total set of cancer-free
controls equalled 4961. The characteristics of these subjects are described in table 1.
Lymphoma occurred a mean of 12.4 years (SD 9.6, median 10.9) after SLE diagnosis. Most
(72) of the lymphomas were non-Hodgkin lymphoma, and the other three were Hodgkin
lymphoma, with most (54) of the lymphomas arising from a B-cell line (nine were from a T-
cell line, and in the remainder the histology was unavailable). In just over 20% of the
lymphoma cases in the analysis (16 of the 75), secondary Sjogren’s syndrome was
diagnosed before the malignancy. Table 2 portrays the results of our unadjusted and adjusted
analyses. As is consistent with the risk profile in the general population, lymphoma risk in
SLE was higher in male than female patients and increased with age.
Of the 75 lymphoma cases, only 15 had prior exposure to cyclophosphamide, 19 to AZA,
nine to methotrexate, and six to mycophenolate mofetil. In a slight majority (42/75=56%) of
the lymphoma cases, there was no prior exposure to any of these immunosuppressants (vs
48% of cancer-free controls being unexposed). Cyclophosphamide was the only
immunosuppressive drug exposure that tended to be higher in frequency in the lymphoma
cases (20.0%) than in the controls (16.8%), although the CI for the difference between these
two proportions includes the null value (of zero difference).
In univariate analyses and in our partially adjusted model (where covariates included age,
sex, Sjogren’s, cyclophosphamide, cumulative steroid and disease activity), a twofold
increased risk of lymphoma was seen with both cyclophosphamide exposure and cumulative
steroid of at least 3.5 g. However, in the fully adjusted model, the CI included the null value
for both. In absolute terms, patients with SLE exposed to cyclophosphamide still had a
relatively low rate of lymphoma occurrence, with fewer than one new case of lymphoma per
1000 person-years of observation time (after cyclophosphamide exposure).
Regarding diseases activity, as can be seen in table 2, there was no clear independent
association of disease activity and lymphoma risk in SLE, in either univariate or adjusted
analyses.
Excluding the two centres where disease activity measures were based on patient self-report
items only, sensitivity analyses showed similar results (data not shown). In addition, when
we lagged exposures, or restricted our analyses to B-cell lymphomas only, the results were
essentially unchanged.
DISCUSSION
Our findings do not clearly substantiate that medication exposures drive most of the
lymphoma risk in SLE. In fact, many of the lymphoma cases were not exposed to any
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immunosuppressant medications before the onset of the malignancy. On the other hand,
there was a trend for a higher proportion of lymphoma cases being exposed to
cyclophosphamide versus the cancer-free controls.
In addition, we found no clear relationship between SLE disease activity and lymphoma
risk. This is in contrast with rheumatoid arthritis (RA), where Baecklund et al9 suggested a
strong association between disease activity and lymphoma risk. A priori, one might suspect
that high disease activity in SLE, which is associated with heightened lymphocyte
proliferation, might also heighten lymphoma risk. However, it is also known that the
immune system has important roles in deleting abnormal cells.10 Interestingly, in a recent
study performed in a mouse model, inflammation driven by tumour-specific Th1 cells
protected against B-cell lymphomas.11 Moreover, some novel evidence suggests that anti-
DNA antibodies may have antitumour effects (in vitro and in animal models) against certain
cancer cell lines (including breast, ovarian and prostate);12 in the current dataset, we saw no
association between the presence of anti-DNA antibodies and lymphoma risk (data not
shown).
Our study has important strengths. The case–cohort design represents flexible and efficient
methodology.13 The cancer registries we used are an excellent tool for cancer ascertainment.
Each registry is patient-based and records the kind and number (incidence) of primary
cancers diagnosed for each resident of the region, as long as they remain alive and residing
there. In addition to information on cancer incidence, data are available about the
characteristics of patients (age, sex, etc), as well as about the nature and type of these
tumours. The registries also use specialised internal record linkage software for detecting
duplicate records and for identifying death records.
Our work builds on previous efforts to determine what factors may predispose to
malignancy in SLE, and is reassuring in that we did not see a marked increased risk in
lymphoma related to most immunosuppressants. However, one great difficulty has always
been differentiating the effects of medications from disease activity. That we were able to
examine the independent effects of medication and disease activity is a strength of our work.
On the other hand, perhaps some elements of disease severity may not be well-captured in
our approach. In considering the association between cumulative glucocorticosteroids and
lymphoma risk, it may be that this variable is a marker for residual differences in disease
activity, not captured by our measures. Furthermore, it is possible that any effect of
medications (eg, cyclophosphamide or steroids) may be due to the emergence of oncogenic
viruses (eg, Epstein–Barr virus). Evaluation of this hypothesis is beyond the scope of this
paper.
Although we collected exposure information on immunosuppressive drugs other than
cyclophosphamide and AZA (eg, mycophenolate), these exposures were not of sufficient
frequency to warrant calculation of cumulative doses. The numbers of patients receiving
mycophenolate were relatively small, reflecting in part the fact that this agent was not in
general use for SLE for the earliest years of observation, although there certainly has been a
general increase over time in the use of this agent. Future analyses could be useful for
monitoring its long-term effects on the development of malignancies. Finally, the variable
for secondary Sjogren’s syndrome was based on clinical judgment and thus we remain very
cautious regarding the influence of this variable on lymphoma risk in SLE.
Previous publications are consistent with our findings, including a review of patients with
SLE (N=15) and RA (N=11) with lymphoproliferative neoplasms.14 In that series, previous
exposure to immunosuppressants (cyclophosphamide, AZA, methotrexate) was relatively
low (fewer than half of the cases had been exposed to any of these drugs). A similar review
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of lymphomas in 12 RA and two SLE patients found that none were exposed to AZA or
cyclophosphamide (five of the RA patients were exposed to methotrexate).15 In addition, in
logistic regression analyses (controlling for disease activity), in 1992, Pettersson et al16 did
not find immunosuppressants to be a cancer risk factor in a small SLE sample (N=205).
On the other hand, in our study, cyclophosphamide did tend to be a more common exposure
in lymphoma cases than controls, and, in both unadjusted and adjusted analyses, the HR
point estimate for cyclophosphamide was >1, which is consistent with a potentially
increased risk. The partially adjusted analyses based on stepwise selection may be
potentially misleading in terms of bias and artificially narrow CIs.17 Fortunately, the
findings in the fully adjusted model support the findings in the partially adjusted model,
which is reassuring.
Our work suggests a potential role for cyclophosphamide in some of the lymphomas that
arise in SLE. However, the number of patients with lymphoma receiving cyclophosphamide
is small (15; table 1). Regarding the route of administration, we were not provided with
complete data for cyclophosphamide, but, in centres that did provide this information, the
vast majority of cyclophosphamide exposures were intravenous. Exclusion of the few
patients known to have received oral cyclophosphamide did not alter our results. Regarding
cumulative cyclophosphamide, we used the cut-off of 6 g to reflect the fairly standard
modern approach to cyclophosphamide use over the past decade at least, where clinicians
tend to decrease exposure, wherever possible, to no more than 3–6 months of monthly
intravenous pulses (which tend to be about 1000 mg per pulse).
Certainly the literature has consistently highlighted cyclophosphamide as a potential
mediator of risk in rheumatic diseases, including RA and vasculitis,18 for haematological,
skin and bladder cancers. However, confounding by disease activity is a potential
concern.19–21 It is known that many adverse drug events are driven by genetic profiles
related to drug metabolism,22 such as cytochrome P450 genotypes. This could be the focus
of future studies of cancer risk in SLE. Although it is beyond the scope of this paper, there is
great clinical interest in what treatments patients with SLE receive for their lymphomas, and
how this might have affected later outcomes. Our earlier study of survival in SLE after
lymphoma suggested that the patients with SLE who developed non-Hodgkin lymphoma do
not fare as well as most general population patients with non-Hodgkin lymphoma.23 In those
analyses, lymphoma cases in SLE were often aggressive and at a fairly advanced stage at
presentation. If more aggressive tumour types or late stage of presentation are more common
in SLE, this might lead to a lower than expected survival, regardless of treatment. Finally,
although in our own experience, the cases of non-Hodgkin lymphoma that develop in
patients with SLE who receive agents such as rituximab may initially do well, some of them
will still eventually succumb to the lymphoma.24
In conclusion, we did not see evidence of disease activity as an independent risk factor for
lymphoma in SLE. We found a suggestion of an increase after cyclophosphamide exposure,
as well as after higher cumulative steroid use. The absolute number of lymphomas among
subjects exposed to cyclophosphamide was relatively small, and the drug remains currently
important for very severe SLE manifestations. However, this work supports an approach to
SLE treatment that weighs both the pros (in terms of prevention of organ damage) and cons
(in terms of long-term adverse events) for these exposures.
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Table 1
Characteristics of lymphoma SLE cases and the cancer-free SLE controls
Characteristic Lymphoma cases (n=75) Cancer-free (n=4961)
Age at entry (years), mean (SD)* 45.2 (14.5) 38.5 (13.8)
Female 60 (80.0) 4511 (90.9)
White 53 (70.0) 3049 (61.5)
Sjogren’s syndrome 16 (21.3) 983 (19.8)
Disease duration at entry (years), mean (SD)† 6.2 (8.1) 6.2 (7.5)
Disease activity at entry, mean (SD)‡ 5.2 (4.9) 6.3 (6.6)
Glucocorticosteroids ever used§ 58 (77.3) 3959 (79.8)
Cyclophosphamide ever used 15 (20.0) 834 (16.8)
Azathioprine ever used 19 (25.3) 1717 (34.6)
Methotrexate ever used 9 (12.0) 960 (19.4)
Mycophenolate mofetil ever used 6 (8.0) 884 (17.8)
Antimalarial drugs ever used¶ 55 (73.3) 4022 (81.1)
Unless otherwise indicated, values are number (%).
*
Median age was 47.3 in lymphoma cases and 37.1 in controls.
†
Median disease duration at cohort entry was 3.1 for cases and 3.5 for controls.
‡
SLE Disease Activity Index-2K (SLEDAI-2K); median value was 4 for both cases and controls.
§
Only systemic steroid exposures were included.
¶
Antimalarial drugs included hydroxycholoroquine and chloroquine.
SLE, systemic lupus erythematosus.













Bernatsky et al. Page 11
Table 2
Results of the unadjusted, partially adjusted and fully adjusted models to assess the HR of exposures in
lymphoma development in patients with systemic lupus erythematosus (SLE)
Variable Unadjusted HR (95% CI)
Partially adjusted model (95%
CI) Fully adjusted HR (95% CI)
Outside North America 0.81 (0.46 to 1.45) – 0.91 (0.44 to 1.90)
Calendar year 1.02 (0.99 to 1.04) – 0.99 (0.96 to 1.02)
Male 2.74 (1.45 to 5.19) 2.64 (1.39 to 5.02) 2.70 (1.38 to 5.28)
Age 1.04 (1.03 to 1.06) 1.04 (1.02 to 1.06) 1.04 (1.02 to 1.06)
White race/ethnicity 1.11 (0.67 to 1.84) – 0.91 (0.53 to 1.56)
Sjogren’s syndrome 2.08 (1.13 to 3.8) 1.94 (1.04 to 3.61) 1.79 (0.88 to 3.62)
Glucocorticosteroids ever used 1.69 (0.95 to 3.03) – 0.79 (0.25 to 2.45)
Cumulative glucocorticosteroids >3.5 g* 1.82 (1.06 to 3.14) 1.94 (1.11 to 3.39) 2.57 (0.94 to 7.04)
Cyclophosphamide ever used 2.07 (1.13 to 3.81) 1.90 (1.02 to 3.53) 2.80 (0.87 to 8.98)
Cumulative cyclophosphamide >6 g 1.68 (0.80 to 3.55) – 0.68 (0.18 to 2.59)
Azathioprine (AZA) ever used 0.72 (0.41 to 1.27) – 0.84 (0.32 to 2.25)
Cumulative AZA >36.5 g 0.55 (0.27 to 1.11) – 0.59 (0.18 to 1.92)
Methotrexate ever used 1.06 (0.50 to 2.26) – 0.74 (0.31 to 1.78)
Mycophenolate ever used 1.47 (0.61 to 3.54) – 1.47 (0.58 to 3.71)
Antimalarial drugs ever used 1.63 (0.94 to 2.84) – 1.55 (0.81 to 2.96)
High disease activity† 0.62 (0.34 to 1.13) 0.65 (0.35 to 1.22) 0.68 (0.36 to 1.29)
*
Systemic glucocorticosteroids, considered in prednisone equivalent doses.
†
Defined as Mean Adjusted SLE Disease Activity Index-2K (SLEDAI-2K) value of 6 or more. For centres using alternative disease activity
measures, high activity was defined as the highest quartile of the mean adjusted activity scores.
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